{"schema_version":"secwatch.filing_event.v1","accession":"0001583648-22-000061","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.255423+00:00","generated_at":"2026-06-24T04:08:00.350032+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pieris CMO Tim Demuth steps down effective Sept 30, 2022; severance of €265,125","bullets":["Tim Demuth, M.D., Ph.D., Senior VP and CMO, mutually agreed to depart Pieris; effective September 30, 2022.","Separation agreement includes 2 months base salary continuation and retirement contributions through Separation Date.","Dr. Demuth will receive a pro-rata 2022 discretionary bonus and severance of €265,125 (~$270,427).","Payments subject to release of claims and ongoing confidentiality obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001583648-22-000061","json":"https://secwatch.observer/filing/0001583648-22-000061.json","markdown":"https://secwatch.observer/filing/0001583648-22-000061.md","text":"https://secwatch.observer/filing/0001583648-22-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000158364822000061/0001583648-22-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000158364822000061/pirs-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:08:00.350032+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb09599fed","claim":"Tim Demuth departed as Senior Vice President and Chief Medical Officer at PALVELLA THERAPEUTICS, INC..","evidence_excerpt":"On August 4, 2022, Pieris Pharmaceuticals, Inc. (together with its wholly-owned subsidiary, Pieris Pharmaceuticals GmbH, the \" Company \") announced that Tim Demuth, M.D., Ph.D. has mutually agreed with the Company to step down effective September 30, 2022 (\"Separation Date\").","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583648/000158364822000061/0001583648-22-000061-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Senior Vice President and Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}